发明名称 |
Pharmaceutical compositions of 5,7,14-triazatetracyclo [10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
摘要 |
<p>Disclosed is a controlled release dosage form suitable for administration to a subject comprising 5,8,14-triazatetra-cyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, and a means for administering the compound to the subject at a rate of less than about 6 mg/hour, whereby the controlled release dosage form is formulated such that at least about 0.1 mg of the compound is administered over a 24 hour period. Also disclosed is a controlled release dosage form formulated such that, when dosed to a subject the dosage form results in a time for maximum plasma concentration (Tmax) that is increased for the drug in an initial administration to the subject by an average of 50% of the corresponding Tmax determined for an equal does of the pentaene in the form of an immediate release bolus. Also disclosed is a controlled release dosage form formulated such that the dosage releases the pentaene at a rate of less than 6 mgA/hr in vitro when dissolution tested in a USP-2 apparatus, such that the time for dissolution of 50 w/w% of the drug is between 1 and 15 hours.</p> |
申请公布号 |
NZ532435(A) |
申请公布日期 |
2005.04.29 |
申请号 |
NZ20020532435 |
申请日期 |
2002.11.04 |
申请人 |
PFIZER PRODUCTS INC |
发明人 |
AM ENDE, MARY TANYA;ROY, MICHAEL CHRISTOPHER;SMITH, SCOTT WENDELL;WATERMAN, KENNETH CRAIG;MOSES, SARA KRISTEN;QUAN, ERNEST SHING |
分类号 |
A61K9/22;A61K9/20;A61K9/26;A61K9/28;A61K31/495;A61K31/4985;A61K47/02;A61K47/10;A61K47/34;A61K47/36;A61K47/38;A61P1/00;A61P1/04;A61P3/04;A61P9/00;A61P9/10;A61P9/12;A61P25/02;A61P25/06;A61P25/14;A61P25/16;A61P25/18;A61P25/20;A61P25/22;A61P25/24;A61P25/28;A61P25/30;A61P25/32;A61P25/34;A61P25/36;A61P37/02;(IPC1-7):A61K47/38 |
主分类号 |
A61K9/22 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|